

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden	
hours per response:	0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>GORDON CARL L</u> (Last) (First) (Middle) <u>767 THIRD AVENUE</u> (Street) <u>NEW YORK NY 10017</u> (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>ACADIA PHARMACEUTICALS INC [ACAD]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director 10% Owner Officer (give title below) Other (specify below)
	3. Date of Earliest Transaction (Month/Day/Year) <u>06/02/2004</u>	
4. If Amendment, Date of Original Filed (Month/Day/Year)		

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	06/02/2004		C		531,606	A	(1)	531,606	I	See Footnotes(2)(3)
Common Stock	06/02/2004		C		354,403	A	(1)	354,403	I	See Footnotes(3)(4)
Common Stock	06/02/2004		P		90,000	A	\$7	621,606	I	See Footnotes(2)(3)
Common Stock	06/02/2004		P		60,000	A	\$7	414,403	I	See Footnotes(3)(4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	V	(A)	(D)	Date Exercisable	Expiration Date						Title
Series E Convertible Preferred Stock	(5)	06/02/2004		C			253,828	(6)	(7)	Common Stock	253,828	(7)	0	I	See Footnotes(2)(3)
Series F Convertible Preferred Stock	(5)	06/02/2004		C			277,778	(6)	(7)	Common Stock	277,778	(7)	0	I	See Footnotes(2)(3)
Series E Convertible Preferred Stock	(5)	06/02/2004		C			169,218	(6)	(7)	Common Stock	169,218	(7)	0	I	See Footnotes(3)(4)
Series F Convertible Preferred Stock	(5)	06/02/2004		C			185,185	(6)	(7)	Common Stock	185,185	(7)	0	I	See Footnotes(3)(4)

Explanation of Responses:

- N/A - Securities were issued upon conversion of convertible preferred stock.
- By Eaton Vance Worldwide Health Sciences Fund.
- The reporting person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest in such securities, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of securities for purposes of Section 16 or any other purpose.
- By Finsbury Worldwide Pharmaceutical Trust.
- 1-for-1.
- Immed.
- N/A

Remarks:

Carl L. Gordon

06/02/2004

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

